Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma

Radioiodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC) following total thyroidectomy. Nevertheless, about 5% of patients with DTC are RAI-refractory (RAI-R). Understanding the molecular mechanisms associated with DTC during progression towards RAI-R DTC, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Samimi, Hilda, Haghpanah, Vahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812241/
https://www.ncbi.nlm.nih.gov/pubmed/35114985
http://dx.doi.org/10.1186/s12935-022-02484-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812241/
https://www.ncbi.nlm.nih.gov/pubmed/35114985
http://dx.doi.org/10.1186/s12935-022-02484-3

Ejemplares similares